Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
---|---|---|---|---|---|---|
FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
DR.REDDYS LABORATORIES LTD. | 88624.0 | 14099.0 | 85721.0 | 17.02 | 1,05,834 | 18.6 |
Mankind Pharma Limited | 26055.8 | 4127.6 | 25413.6 | 9.99 | 105278 | 55.7 |
Zydus Lifesciences Limited | 27454.0 | 3847.0 | 25883.0 | 3.82 | 102017 | 21.9 |
Dr. Reddy's Laboratories Ltd.,, with Security Code 500124, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Sales | 3,897.6 | 4,554.0 | 5,437.3 | 4,838.7 | 4,103.0 | 5,104.8 | 5,841.2 | 6,696.3 | 5,015.0 | 5,562.9 |
Expenses | 3,222.5 | 3,492.9 | 3,209.6 | 3,209.6 | 3,446.7 | 3,726.2 | 3,888.2 | 3,974.7 | 3,822.6 | 4,119.9 |
Operating Profit | 675.1 | 1,061.1 | 2,227.7 | 1,629.1 | 656.3 | 1,378.6 | 1,953.0 | 2,721.6 | 1,192.4 | 1,443.0 |
OPM % | 17.32% | 23.3% | 40.97% | 33.67% | 16% | 27.01% | 33.43% | 40.64% | 23.78% | 25.94% |
Other Income | 51.4 | 114.8 | 233.6 | 223.1 | 227.6 | 212.7 | 217.8 | 207.6 | 235.4 | 414.4 |
Interest | 2.8 | 2.6 | 4.5 | 5.8 | 5.6 | 5.9 | 7.1 | 28.4 | 43.3 | 31.1 |
Depreciation | 238.8 | 236.7 | 237.2 | 245.8 | 246.4 | 246.2 | 249.8 | 260.0 | 265.1 | 264.5 |
Profit before tax | 484.9 | 936.6 | 2,219.6 | 1,600.6 | 631.9 | 1,339.2 | 1,913.9 | 2,640.8 | 1,119.4 | 1,561.8 |
Tax % | -33.1% | -28.2% | -26.1% | -25.5% | -24.8% | -22.7% | 26% | -28.7% | -24.1% | -23.1% |
Net Profit | 324.6 | 672.4 | 1,639.4 | 1,192.6 | 475.2 | 1,034.8 | 1,417.2 | 1,882.1 | 849.4 | 1,200.7 |
EPS in Rs | 3.9 | 8.08 | 19.69 | 14.31 | 5.7 | 12.41 | 16.99 | 22.56 | 10.18 | 0 |
Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Sales | 6,315.2 | 6,757.9 | 6,902.6 | 7,236.8 | 7,113.8 | 7,696.1 | 8,038.2 | 8,381.2 | 8,528.4 | 8,572.1 |
Expenses | 4,781.3 | 4,695.8 | 4,894.3 | 5,213.7 | 5,282.6 | 5,566.2 | 5,961.7 | 6,108.2 | 6,530.5 | 6,398.5 |
Operating Profit | 1,533.9 | 2,062.1 | 2,008.3 | 2,023.1 | 1,831.2 | 2,129.9 | 2,076.5 | 2,273.0 | 1,997.9 | 2,173.6 |
OPM % | 24.29% | 30.51% | 29.09% | 27.96% | 25.74% | 27.68% | 25.83% | 27.12% | 23.43% | 25.36% |
Other Income | 138.5 | 174.0 | 315.0 | 216.2 | 197.5 | 187.2 | 307.5 | 150.2 | 522.1 | 290.3 |
Interest | 35.4 | 37.1 | 35.3 | 39.4 | 59.3 | 59.8 | 75.7 | 81.7 | 65.6 | 83.0 |
Depreciation | 315.5 | 353.3 | 375.5 | 373.5 | 367.7 | 380.6 | 397.0 | 471.4 | 454.7 | 476.1 |
Profit before tax | 1,321.5 | 1,845.7 | 1,912.5 | 1,826.4 | 1,601.7 | 1,876.7 | 1,911.3 | 1,870.1 | 1,999.7 | 1,904.8 |
Tax % | -27.9% | -24.1% | -22.7% | -24.5% | -18.4% | -26.1% | 30.1% | -25.1% | -20.9% | 26% |
Net Profit | 960.1 | 1,405.0 | 1,482.2 | 1,380.9 | 1,309.8 | 1,392.4 | 1,341.9 | 1,404.2 | 1,586.7 | 1,409.9 |
EPS in Rs | 11.54 | 16.87 | 17.78 | 16.56 | 15.71 | 16.7 | 15.05 | 16.94 | 0 | 17.02 |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 14% |
3 Years: | 17% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 13% |
3 Years: | 49% |
TTM: | 25% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | 9% |
3 Years: | 12% |
1 Year: | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 13% |
3 Years: | 15% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 23% |
3 Years: | 39% |
TTM: | 3% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | 9% |
3 Years: | 12% |
1 Year: | 4% |
Recent Bets
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
---|
Period | SMA Value | Status |
---|
Period | EMA Value | Status |
---|
Indicator | Value |
---|